Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Apr;29(4):670–674. doi: 10.1128/aac.29.4.670

Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.

R F Jacobs, G L Kearns, A L Brown, D C Longee
PMCID: PMC180464  PMID: 3458427

Abstract

Cerebrospinal fluid (CSF) penetration of imipenem-cilastatin was evaluated in 20 children (aged 4 months to 11 years) with central nervous system infections. A total of 10 children received a single 25-mg/kg intravenous dose, and 10 received three 25-mg/kg intravenous doses at 6-h intervals. Blood and CSF were obtained 1.5 to 2.5 h after the last dose during the early (days 1 to 3) and the late (days 7 to 10) stages of infection. Imipenem concentrations after single-dose infusion in serum and CSF during the early phase of treatment (8.59 +/- 0.95 and 1.36 +/- 0.32 micrograms/ml, respectively) were similar to those during the late phase (9.96 +/- 2.36 and 2.08 +/- 1.14 micrograms/ml, respectively). Concentrations of imipenem in serum and CSF after multiple-dose infusion during the early phase (11.97 +/- 2.03 and 1.87 +/- 0.29 micrograms/ml, respectively) were similar to those during the late phase (9.57 +/- 1.76 and 1.22 +/- 0.11 micrograms/ml, respectively). There were no significant differences in the serum or CSF imipenem concentrations between the single- and multiple-dose groups during the early or late treatment stages. Cilastatin concentrations in serum and CSF were similar in all groups with the exception of the multiple-dose, early- versus late-phase evaluation of CSF cilastatin concentration. There was no correlation between age or absolute CSF neutrophil count and the serum or CSF concentrations of imipenem or cilastatin. We found a mean CSF penetration of 15 to 27% for imipenem and 16 to 66% for cilastatin in children. These findings suggest that imipenem-cilastatin sufficiently penetrates into CSF in children to warrant further investigation of this compound in pediatric central nervous system infections.

Full text

PDF
670

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blumer J. L., Aronoff S. C., Myers C. M., O'Brien C. A., Klinger J. D., Reed M. D. Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis. Dev Pharmacol Ther. 1985;8(4):219–231. doi: 10.1159/000457041. [DOI] [PubMed] [Google Scholar]
  2. Brotherton T. J., Kelber R. L. Seizure-like activity associated with imipenem. Clin Pharm. 1984 Sep-Oct;3(5):536–540. [PubMed] [Google Scholar]
  3. Chow A. W., Finlay K. R., Stiver H. G., Carlson C. L. Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor. Antimicrob Agents Chemother. 1983 Apr;23(4):634–636. doi: 10.1128/aac.23.4.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gutiérrez-Núez J., Harrington P. T., Ramirez-Ronda C. H. Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia. Antimicrob Agents Chemother. 1982 Mar;21(3):509–512. doi: 10.1128/aac.21.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jacobs R. F., Kearns G. L., Trang J. M., Brown A. L., Marmer B., McIntosh J. C., Underwood F. L., Kluza R. B. Single-dose pharmacokinetics of imipenem in children. J Pediatr. 1984 Dec;105(6):996–1001. doi: 10.1016/s0022-3476(84)80098-0. [DOI] [PubMed] [Google Scholar]
  6. Kahan J. S., Kahan F. M., Goegelman R., Currie S. A., Jackson M., Stapley E. O., Miller T. W., Miller A. K., Hendlin D., Mochales S. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979 Jan;32(1):1–12. doi: 10.7164/antibiotics.32.1. [DOI] [PubMed] [Google Scholar]
  7. Livingston W. K., Elliott A. M., Cobbs C. G. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp. Antimicrob Agents Chemother. 1981 Jan;19(1):114–116. doi: 10.1128/aac.19.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Myers C. M., Blumer J. L. Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1984 Jul;26(1):78–81. doi: 10.1128/aac.26.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Neu H. C., Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother. 1982 Jan;21(1):180–187. doi: 10.1128/aac.21.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Patamasucon P., McCracken G. H., Jr Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 1982 Mar;21(3):390–392. doi: 10.1128/aac.21.3.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schaad U. B., McCracken G. H., Jr, Loock C. A., Thomas M. L. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis. 1981 Feb;143(2):156–163. doi: 10.1093/infdis/143.2.156. [DOI] [PubMed] [Google Scholar]
  12. Skopnik H., Heimann G. Pharmacokinetics of antimicrobial drugs in the cerebrospinal fluid. Pediatr Pharmacol (New York) 1983;3(3-4):313–320. [PubMed] [Google Scholar]
  13. Verbist L., Verhaegen J. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Mar;19(3):402–406. doi: 10.1128/aac.19.3.402. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES